Sort
10,766 grants matching “checkpoint inhibitor”
Project 2: Transcriptional Dynamics and Temporal Reprogramming During Radiation Treatment
$176,714Jacob Gardinier Scott · Cleveland Clinic Lerner Com-Cwru · U54 · FY2025 · CA
An innate immune checkpoint in cancer immunotherapy
$176,697Carla Rothlin · Yale University · R01 · FY2019 · CA
Blocking ligand-dependent BMP signaling as an anti-melanoma strategy
$176,690Craig Joseph Ceol · Univ Of Massachusetts Med Sch Worcester · R21 · FY2019 · CA
BLOOD TYPES AS TUMOR- ASSOCIATED CARBOHYDRATE ANTIGENS THAT DETERMINE THE EFFICACY OF IMMUNE CHECKPOINT INHIBITOR THERAPY IN LUNG CANCER.
$176,655Children'S Hospital Corporation, The · · FY2022 · Defense Health Agency
Project 3: Immune Checkpoint Inhibition Therapy Enhanced by Integrated Photodynamic Treatment and Image Guidance in Preclinical Models of Pancreatic Cancer
$176,620Tayyaba Hasan · Massachusetts General Hospital · P01 · FY2023 · CA
Computerized platform for interactive annotation and topological characterization of tumor associated vasculature for predicting response to immunotherapy in lung cancer
$176,525Prateek Prasanna · State University New York Stony Brook · R21 · FY2023 · CA
Targeting USP10 to regulate the DNA damage response in NSCLC
$176,389Xiaohong Mary Zhang · Wayne State University · R21 · FY2022 · CA
Immunological manipulation of resistance to molecularly targeted inhibitors
$176,175Mary J Turk · Dartmouth College · R21 · FY2016 · CA
Microbiota and the anti-tumor action of anti-CD47 immunomodulation.
$176,175Ralph R Weichselbaum · University Of Chicago · R21 · FY2019 · CA
Predictive modeling of cutaneous immune checkpoint inhibitor toxicities
$176,040Yevgeniy R Semenov · Massachusetts General Hospital · K23 · FY2025 · AR
Breaching the Tumor-Immune Mechanical Barrier for Optimal Antitumor Immunity
$176,040Bogang Wu · Massachusetts General Hospital · K99 · FY2025 · CA
Breaching the Tumor-Immune Mechanical Barrier for Optimal Antitumor Immunity
$176,040Bogang Wu · Massachusetts General Hospital · K99 · FY2024 · CA
Predictive modeling of cutaneous immune checkpoint inhibitor toxicities
$176,040Yevgeniy R Semenov · Massachusetts General Hospital · K23 · FY2023 · AR
Predictive modeling of cutaneous immune checkpoint inhibitor toxicities
$176,040Yevgeniy R Semenov · Massachusetts General Hospital · K23 · FY2024 · AR
Full Project 1: Understanding and Targeting of Convergent Immunosuppressive Pathways and Molecular Signaling in HPV-positive and HPV-negative Penile Cancer
$175,821Curtis Pettaway · University Of Tx Md Anderson Can Ctr · U54 · FY2019 · CA
A synthetic lethal approach for targeting p53 deficient triple negative breast cancer
$175,429Carl G Maki · Rush University Medical Center · R21 · FY2024 · CA
Mechanisms of Thyroid Autoimmunity in Checkpoint Immunotherapy
$175,392Melissa G Lechner · University Of California Los Angeles · K08 · FY2022 · DK
Mechanisms of Thyroid Autoimmunity in Checkpoint Immunotherapy
$175,392Melissa G Lechner · University Of California Los Angeles · K08 · FY2024 · DK
Mechanisms of Thyroid Autoimmunity in Checkpoint Immunotherapy
$175,392Melissa G Lechner · University Of California Los Angeles · K08 · FY2023 · DK
Mechanisms of Thyroid Autoimmunity in Checkpoint Immunotherapy
$175,392Melissa G Lechner · University Of California Los Angeles · K08 · FY2025 · DK
Engineering class I MHC molecules to drive enhanced anti-cancer responses
$175,320David M Kranz · University Of Illinois At Urbana-Champaign · R21 · FY2021 · CA
Targeting MerTK as an immunotherapeutic strategy in acute myeloid leukemia
$175,285Alisa Lee Sherick · University Of Colorado Denver · K08 · FY2019 · CA
Targeting MerTK as an immunotherapeutic strategy in acute myeloid leukemia
$175,285Alisa Lee Sherick · University Of Colorado Denver · K08 · FY2022 · CA
Targeting MerTK as an immunotherapeutic strategy in acute myeloid leukemia
$175,285Alisa Lee Sherick · University Of Colorado Denver · K08 · FY2020 · CA
Targeting MerTK as an immunotherapeutic strategy in acute myeloid leukemia
$175,285Alisa Lee Sherick · University Of Colorado Denver · K08 · FY2021 · CA